Advertisement

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

David A. Hyman, MD, JD, on Inclusive Shared Savings

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Advertisement

Advertisement




Jul
13
Today In Oncology
Study Supports Multi-Contaminant Water Treatment to Reduce Cancer Risk
New Research Offers Reassurance About Localized Prostate Cancer Prognosis
Avelumab Plus Cetuximab in Advanced Cutaneous Squamous Cell Carcinoma
Surgery vs Ablation in Small Hepatocellular Carcinoma
Chemoimmunotherapy for Advanced BTC 3-Year Overall Survival Update From the TOPAZ Trial
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo